Levin Capital Strategies’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.05M | Sell |
289,147
-875,454
| -75% | -$15.3M | 0.49% | 49 |
|
|
2025
Q1 | $14.7M | Buy |
1,164,601
+696,974
| +149% | +$8.77M | 1.55% | 23 |
|
|
2024
Q4 | $4.93M | Buy |
467,627
+198,201
| +74% | +$2.09M | 0.47% | 51 |
|
|
2024
Q3 | $3.91M | Buy |
269,426
+186,176
| +224% | +$2.7M | 0.37% | 53 |
|
|
2024
Q2 | $708K | Buy |
83,250
+28,000
| +51% | +$238K | 0.07% | 95 |
|
|
2024
Q1 | $565K | Buy |
55,250
+3,000
| +6% | +$30.7K | 0.06% | 117 |
|
|
2023
Q4 | $286K | Sell |
52,250
-11,750
| -18% | -$64.4K | 0.03% | 165 |
|
|
2023
Q3 | $242K | Sell |
64,000
-105,074
| -62% | -$397K | 0.03% | 188 |
|
|
2023
Q2 | $1.13M | Buy |
169,074
+28,723
| +20% | +$192K | 0.13% | 82 |
|
|
2023
Q1 | $914K | Buy |
140,351
+101,341
| +260% | +$660K | 0.11% | 85 |
|
|
2022
Q4 | $333K | Buy |
+39,010
| New | +$333K | 0.04% | 146 |
|